The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages...
For almost 25 years, the CHS has played a key role in raising awareness about bleeding disorders that affect women. In 2012, to ensure the...
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
The World Federation of Hemophilia SDM Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between people with hemophilia A or...
Montreal, August 10, 2023 – Gene therapies for hemophilia A and B continue to move closer to becoming reality. Health Canada is currently evaluating two...
Kilimanjaro, the roof of Africa, a dormant volcano of 5,895 meters in height is a major hiking and climbing destination that about 35,000 people attempt...
The Canadian bleeding disorder treatment centres participed in a rigorous self-assessment of their services from November 2022 to February 2023. IT IS NOW TIME TO...
The 1st gene therapy for hemophilia B (factor IX deficiency) is currently undergoing an evaluation by Canadian health authorities. This review will determine whether or...
As the result of the latest actuarial study to the end of the year 2019, the Joint Committee announced in early 2021 that the Fund...
On Friday, June 30, Maia Meier and Craig Upshaw, longstanding CHS volunteers, will start their climb to the top of Mount Kilimanjaro. Both Maia and...
It was with great pride that the CHS learned that the World Federation of Hemophilia (WFH) had granted the 2022 Hemophilia Organization Twins of the...
The CHS is deeply saddened to learn of the passing of Dr. Ronald George. We would like to offer our sincere condolences to his wife...
CLICK HERE to meet the 2023 James Kreppner Scholarship and Bursary recipients.
Montreal – May 23, 2023 – The Canadian Hemophilia Society has learned that Health Canada recently approved Alhemo (concizumab) for the treatment of people, ages...